Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Metrics to compare | GENF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGENFPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.2x | −3.9x | −0.5x | |
PEG Ratio | −0.15 | −0.04 | 0.00 | |
Price/Book | −8.6x | 2.5x | 2.6x | |
Price / LTM Sales | 11.6x | 6.1x | 3.0x | |
Upside (Analyst Target) | - | 198.7% | 52.7% | |
Fair Value Upside | Unlock | 4.7% | 7.6% | Unlock |